[S-8 POS] Unity Biotechnology, Inc. SEC Filing
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate effectiveness of multiple Form S-8 registration statements and remove from registration all shares that remain unsold under those filings. The amendment deregisters unsold common stock previously registered across ten S-8 filings spanning 2018 to 2025, specifying the original registered share amounts for each plan and noting that listed numbers do not reflect subsequent corporate actions such as stock splits.
Unity Biotechnology ha depositato l'Emendamento Post-Efficace n. 1 per revocare l'efficacia di più dichiarazioni di registrazione in base al Modulo S-8 e per rimuovere dalla registrazione le azioni rimaste invendute previste da tali documenti. L'emendamento cancella la registrazione delle azioni ordinarie invendute precedentemente registrate in dieci depositi S-8 effettuati tra il 2018 e il 2025, indicando gli importi originariamente registrati per ciascun piano e precisando che i numeri riportati non tengono conto di successive operazioni societarie come frazionamenti azionari.
Unity Biotechnology presentó la Enmienda Post-Efectiva n.º 1 para terminar la vigencia de varias declaraciones de registro en Formulario S-8 y eliminar de registro todas las acciones que queden sin vender bajo esos registros. La enmienda da de baja la inscripción de las acciones ordinarias no vendidas registradas anteriormente en diez presentaciones S-8 entre 2018 y 2025, detallando las cantidades originalmente registradas para cada plan y señalando que las cifras listadas no reflejan posteriores acciones corporativas como los desdoblamientos de acciones.
Unity Biotechnology는 다수의 Form S-8 등록명세서의 효력 종료와 해당 제출서에 따라 미판매 상태로 남아있는 모든 주식의 등록 말소를 위해 효력 이후 수정안(Post-Effective Amendment) 제1호를 제출했습니다. 이 수정안은 2018년부터 2025년까지의 10건의 S-8 제출에 따라 이전에 등록된 미판매 보통주의 등록을 말소하며, 각 플랜별로 원래 등록된 주식 수를 명시하고 기재된 수치는 주식분할과 같은 이후 회사 조치를 반영하지 않는다고 밝힙니다.
Unity Biotechnology a déposé l'Amendement Post-Efficace n°1 afin de mettre fin à l'efficacité de plusieurs déclarations d'enregistrement au formulaire S-8 et de retirer de l'enregistrement toutes les actions demeurées invendues dans le cadre de ces dépôts. L'amendement radie de l'enregistrement les actions ordinaires invendues précédemment enregistrées dans dix dépôts S-8 couvrant la période 2018-2025, en précisant les montants initialement enregistrés pour chaque plan et en indiquant que les chiffres énumérés ne tiennent pas compte d'opérations corporatives ultérieures telles que des fractionnements d'actions.
Unity Biotechnology hat die Post-Effective Amendment Nr. 1 eingereicht, um die Wirksamkeit mehrerer Form S-8-Registrierungserklärungen zu beenden und alle unter diesen Einreichungen unveräußerten Aktien aus der Registrierung zu entfernen. Die Änderung deregistriert unveräußerte Stammaktien, die zuvor in zehn S-8-Anmeldungen von 2018 bis 2025 registriert wurden, gibt die ursprünglich für jeden Plan registrierten Stückzahlen an und weist darauf hin, dass die aufgeführten Zahlen spätere gesellschaftliche Maßnahmen wie Aktiensplits nicht berücksichtigen.
- Administrative clarity: The company formally deregistered unsold shares across prior S-8 filings, reducing outstanding registration housekeeping.
- Compliance: Filing follows required undertakings and cites Rule 478, indicating adherence to securities filing procedures.
- Reduced registered capacity: The deregistration removes previously registered but unsold shares, which limits immediately available registered shares for quick issuance under those prior statements.
- No update on replacement registration: The filing does not state whether new registration statements will be filed to replace the removed capacity.
Insights
TL;DR: Routine administrative deregistration removing unsold employee-plan shares; governance impact is limited.
This filing formally terminates the effectiveness of ten Form S-8 registration statements and removes from registration the unsold shares previously registered for employee equity plans and ESPP. The action appears administrative: it aligns registered shares with the company's current capital plan and removes stale registration capacity. There is no new issuance, dilution, or change in compensation policy disclosed here.
TL;DR: Compliance-driven filing to deregister unsold securities under Rule 478; no disclosed material financing or transaction.
The company cites its undertakings under the S-8 registration statements and relies on Rule 478 to terminate effectiveness and deregister remaining unsold common stock. The filing lists the original registered share quantities by filing date and plan, and explicitly disclaims adjustment for interim corporate actions. This is a routine securities-administration step rather than a material market event.
Unity Biotechnology ha depositato l'Emendamento Post-Efficace n. 1 per revocare l'efficacia di più dichiarazioni di registrazione in base al Modulo S-8 e per rimuovere dalla registrazione le azioni rimaste invendute previste da tali documenti. L'emendamento cancella la registrazione delle azioni ordinarie invendute precedentemente registrate in dieci depositi S-8 effettuati tra il 2018 e il 2025, indicando gli importi originariamente registrati per ciascun piano e precisando che i numeri riportati non tengono conto di successive operazioni societarie come frazionamenti azionari.
Unity Biotechnology presentó la Enmienda Post-Efectiva n.º 1 para terminar la vigencia de varias declaraciones de registro en Formulario S-8 y eliminar de registro todas las acciones que queden sin vender bajo esos registros. La enmienda da de baja la inscripción de las acciones ordinarias no vendidas registradas anteriormente en diez presentaciones S-8 entre 2018 y 2025, detallando las cantidades originalmente registradas para cada plan y señalando que las cifras listadas no reflejan posteriores acciones corporativas como los desdoblamientos de acciones.
Unity Biotechnology는 다수의 Form S-8 등록명세서의 효력 종료와 해당 제출서에 따라 미판매 상태로 남아있는 모든 주식의 등록 말소를 위해 효력 이후 수정안(Post-Effective Amendment) 제1호를 제출했습니다. 이 수정안은 2018년부터 2025년까지의 10건의 S-8 제출에 따라 이전에 등록된 미판매 보통주의 등록을 말소하며, 각 플랜별로 원래 등록된 주식 수를 명시하고 기재된 수치는 주식분할과 같은 이후 회사 조치를 반영하지 않는다고 밝힙니다.
Unity Biotechnology a déposé l'Amendement Post-Efficace n°1 afin de mettre fin à l'efficacité de plusieurs déclarations d'enregistrement au formulaire S-8 et de retirer de l'enregistrement toutes les actions demeurées invendues dans le cadre de ces dépôts. L'amendement radie de l'enregistrement les actions ordinaires invendues précédemment enregistrées dans dix dépôts S-8 couvrant la période 2018-2025, en précisant les montants initialement enregistrés pour chaque plan et en indiquant que les chiffres énumérés ne tiennent pas compte d'opérations corporatives ultérieures telles que des fractionnements d'actions.
Unity Biotechnology hat die Post-Effective Amendment Nr. 1 eingereicht, um die Wirksamkeit mehrerer Form S-8-Registrierungserklärungen zu beenden und alle unter diesen Einreichungen unveräußerten Aktien aus der Registrierung zu entfernen. Die Änderung deregistriert unveräußerte Stammaktien, die zuvor in zehn S-8-Anmeldungen von 2018 bis 2025 registriert wurden, gibt die ursprünglich für jeden Plan registrierten Stückzahlen an und weist darauf hin, dass die aufgeführten Zahlen spätere gesellschaftliche Maßnahmen wie Aktiensplits nicht berücksichtigen.
FAQ
What did Unity Biotechnology (UBX) file in this S-8 Post-Effective Amendment?
Which S-8 registration statements were deregistered by Unity Biotechnology?
How many share pools were listed as originally registered under these S-8 filings?
Does the filing indicate any new issuances or financings?
Did Unity note adjustments for corporate actions like stock splits?
